Acadia Pharma (ACAD) Misses Q1 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. SPCX
10. SPY

Go back to Acadia Pharma (ACAD) Misses Q1 EPS by 9c

ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results

May 7, 2020 4:07 PM EDT

- 1Q20 Net Sales of $90.1 Million, a 43% Increase Over 1Q19

- On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related psychosis (DRP) this summer

- Announced worldwide license agreement and collaboration with Vanderbilt University for new central nervous system (CNS) therapeutic program

- 2020 revenue guidance reduced by approximately 5% due to currently anticipated COVID-19 impact

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative... More